A clinical research involving 52 BCBMs patients and 12 matched primary breast cancers indicates that the expression of p‐Akt, p‐S6, and lack of PTEN was observed as 75%, 69%, and 25% separately for BCBMs and as 67%, 58%, 83% for primary breast cancers.56 Both EGFR and PTEN alterations were closely associated with primary triple‐negative breast cancer (TNBC) and high risk of brain relapse.57 On the other hand, RAS/Raf/ERK is also related to EGFR. This evidence concerns the gene AKT1 and breast cancer.